Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are developing methods for the analysis of heparan sulfate (HS) sequences that bind protein partners. In the present work, the antithrombin III is used as a model HS binding protein. The approach is to prepare size fractionated HS oligosaccharides, to bind them to a protein under physiological conditions (isotonic salt). Non-binding oligosaccharides are dialyzed away, and the bound oligosaccharides analyzed. The denaturation step is critical to these procedures. Traditional approaches use high sodium chloride concentrations to disrupt the carbohydrate-protein interactions. We are testing mass spectrometry-friendly approaches for accomplishing this task, including acidic pH, basic pH, and organic solvents. HS is expressed on cell surfaces, in basement membranes and extracellular matrices and is comprised of linear repeating units of GlcNAc?1-4HexA?/?1-4 with variations in the arrangement of sulfated residues and uronic acid epimers. Although it is known that the protein binding interactions of HS are mediated by specific oligosaccharide sequences, methods for structural elucidation lag far behind those used for proteomics. Classical techniques for studying HS interactions involve using heparin lyases with discrete specificities combined with chromatographic or electrophoretic separations for analyzing the enzyme products. The use of size exclusion chromatography (SEC) LC-MS for analysis of different HS lyase digestion samples and resolution of enzyme resistant regions is investigated in this work. Isolated and purified HS chains were subjected to depolymerization using combinations of heparin lyases I, II, and III. The extent of each reaction was monitored using UV spectrophotometry to select appropriate time points for MS analysis. Oligosaccharide products at these time points were analyzed by LC/MS using a Superdex peptide 3.2/30 SEC column, equilibrated with 30% methanol, 0.1% ammonium hydroxide and a Bruker Esquire 3000 ITMS (donated by Bruker Daltonics, Inc.) operating in the negative mode. Optimal resolution was achieved by utilizing flow rates of 30-100 ?l/min and ions were scanned at a rate of 1650 m/z per sec.
No Sub Projects information available for 5P41RR010888-10 7132
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P41RR010888-10 7132
Patents
No Patents information available for 5P41RR010888-10 7132
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P41RR010888-10 7132
Clinical Studies
No Clinical Studies information available for 5P41RR010888-10 7132
News and More
Related News Releases
No news release information available for 5P41RR010888-10 7132
History
No Historical information available for 5P41RR010888-10 7132
Similar Projects
No Similar Projects information available for 5P41RR010888-10 7132